| Target | Th. area | MoA |
Disc.
In vitro/in vivo
Preclin.
Phase 1
Phase 2
Phase 3
|
|
| Pre-Clinical Stage | PLGA-Encapsulated Disulfiram Microparticles | Malignant Mesothelioma |
Proteasome inhibition NF-kB pathway and CSC inhibitor |
|
| Glioblastoma |
|
|||
|
Solid Cancer Peritoneal Metastasis |
|
|||
| DISCAN07424 (for topical application) | Multiple cancers |
Immune regulation Combination therapy agent |
|
|
| Discovery | DISCAN10819 – Liposomes | Multiple Myeloma |
Immune regulation CELMoD like activity Ikaros and Aiolos |
|
| DISCAN10820-Albumin | Pancreatic cancer |
Proteasome inhibition NF-kB pathway and CSC inhibitor |
|
|
| DISCAN164121 – Liposomes | Prostate Cancer |
E3 ligase modulator CSC inhibitor |
|
|
| DISCO V192020 (for topical application) |
COVID/Long COVID Cancer Skin disorders |
Viral replication, Cytokine storm Immune regulation Mpro inhibitor, Zinc ejector Gasdermin inhibitor |
|
